Bioaerosol Efficacy Testing Room studies measure how room-scale or in-duct devices reduce airborne microbial concentrations over time. Controlled chambers, duct sections, nebulized organism surrogates, viable impingers, filter collection, and culture, qPCR, or droplet digital PCR (ddPCR) endpoints support ISO 17025 records and ASHRAE 241 or AHAM AC-1 aligned performance claims:
- Room air cleaner benchmarking under ASHRAE 241 context, using chamber release, viable sampling, and log reduction curves for portable or fixed air-treatment devices.
- UVGI design verification for room or duct systems, using ISO 17025 records, UV dose logging, airflow data, and viable recovery to compare operating modes.
- In-duct HVAC add-on evaluation aligned to ASTM E3273 or ISO 16000-36, using defined flow, organism recovery, and device-off controls for reduction claims.
- EPA OPPT claim support for antimicrobial or air-treatment products, using organism selection, recovery validation, and replicate chamber runs matched to the claim language.
- AHAM AC-1 adjacent air cleaner studies under ISO 17025 records, using controlled bioaerosol challenges and device-off decay baselines to translate particle CADR concepts into microbial reduction data.
Use room bioaerosol efficacy testing when the decision depends on measured microbial reduction under defined airflow, mixing, RH, and temperature conditions. The study plan fixes the organism panel, chamber or duct configuration, endpoints, and aligned standards before testing begins.